Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.48 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19520657 | 1.00 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2770110 | 1.00 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL9314374 | 1.00 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL342640 | 1.00 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL20502714 | 1.00 | F2 (0.54) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL6497247 | 0.96 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2119635 | 0.96 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2778546 | 0.96 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL6850160 | 0.96 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 | |
| SCHEMBL2778544 | 0.96 | F2 (0.57) | F2OPRM1OPRD1OPRK1NPFFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603383-B2 | High capacity diketopiperazine microparticles and methods | MANNKIND CORPORATION (US) | 2020-03-31 | — | — | US | claimed |
| EP-2694970-A2 | DIALYSIS LIKE THERAPEUTIC (DLT) DEVICE | President and Fellows of Harvard College (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012135834-A2 | DIALYSIS LIKE THERAPEUTIC (DLT) DEVICE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-2482840-A2 | VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME | MannKind Corporation (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011017554-A2 | VAL (8) GLP-1 COMPOSITION AND METHOD FOR TREATING FUNCTIONAL DYSPEPSIA AND/OR IRRITABLE BOWEL SYNDROME | MANNKIND CORPORATION (US) | 2011-02-10 | — | — | WO | disclosed |
| EP-2211842-A2 | METHOD OF PREVENTING ADVERSE EFFECTS BY GLP-1 | MannKind Corporation (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009055740-A2 | METHOD OF PREVENTING ADVERSE EFFECTS BY GLP-1 | MANNKIND CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-1997002340-A2 | METHODS FOR INHIBITING FACTOR XIII ACTIVITY | ZYMOGENETICS, INC. (US) | 1997-01-23 | — | — | WO | disclosed |
| EP-0577699-A4 | COMPOSITIONS AND METHODS TO INHIBIT THE ACTIVATION OF ACTIVE FACTOR XIII. | GEN HOSPITAL CORP (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0577699-A1 | COMPOSITIONS AND METHODS TO INHIBIT THE ACTIVATION OF ACTIVE FACTOR XIII | THE GENERAL HOSPITAL CORPORATION (US) | 1994-01-12 | — | — | EP | disclosed |
| WO-1992015609-A1 | COMPOSITIONS AND METHODS TO INHIBIT THE ACTIVATION OF ACTIVE FACTOR XIII | THE GENERAL HOSPITAL CORPORATION (US) | 1992-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10603383-B2 | High capacity diketopiperazine microparticles and methods | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL5, KCNK17 | F2 712/4885OPRM1 2448/4885OPRD1 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.